Jefferies raises Immunocore stock price target on melanoma trial By Investing.com

Jefferies cut Immunocore’s price target to $34 from $33 and maintained a Hold rating, citing that Kimmtrak’s uveal melanoma opportunity appears to be reaching peak levels. The firm pointed to Phase 3 TEBE-AM in cutaneous melanoma as the key upside driver, with enrollment expected to finish in 1H 2026 and potential OS data in Q4 2026. Immunocore reported $400 million in trailing-12-month revenue, 29% growth, and a 96.5% gross margin, but analysts do not expect profitability this year.

Analysis

IMCR is drifting into a classic late-cycle specialty pharma setup: the base business is cash-generative enough to suppress immediate distress, but the equity is being re-rated off a shrinking set of binary milestones. That usually compresses realized upside and leaves the stock increasingly hostage to trial timing rather than operating execution, which explains why the risk/reward is now more about event dispersion than fundamental surprise.

The second-order effect is competitive: as the lead indication matures, capital will likely rotate toward names with earlier readouts or broader addressable markets. That creates a relative-value opportunity within oncology biotech, especially versus programs that can reaccelerate sentiment through ASCO data or faster pivotal timelines. If the upcoming melanoma updates fail to broaden the story, multiple compression can happen even without a revenue miss because the market will start discounting the post-peak slope 12-18 months ahead of the actual plateau.

The macro tape matters for the rest of the basket more than for IMCR. Strength in AMD and record indices can keep biotech risk appetite stable near term, but that support is fragile if rates reprice or if healthcare rotates out of favor on better growth elsewhere. The cleanest way to think about IMCR is as a long-duration catalyst optionality trade with a deteriorating fundamental backstop, not as a core compounder.

Contrarian read: the market may still be underestimating how quickly “peak” narratives metastasize into de-rating in specialty pharma. If melanoma adoption is already saturating, then even modestly positive trial updates may only extend the runway, not expand the terminal value. In that case the stock can look cheap on near-term sales while still being expensive on the next cycle of growth.

Key Decisions for Investors

• Short IMCR into ASCO / key melanoma data windows over the next 1-3 months; thesis is that positive incremental data may be insufficient to offset peak-penetration concerns, with downside >20% if the market re-rates the terminal growth profile.
• Pair trade: long a higher-catalyst oncology name with near-term data visibility vs. short IMCR for relative alpha over 2-6 months; structure to isolate event-driven dispersion rather than market beta.
• Use IMCR only as a tactical long-vol name: buy upside calls or call spreads into the Phase 3 timing window, because the stock’s best-case upside is likely concentrated in discrete readout dates while downside can grind lower if catalysts disappoint.
• Reduce exposure on any post-data strength; if the stock rallies on non-incremental updates, use that move to fade the multiple rather than chase, since the fundamental slope appears to be slowing.
• For broader healthcare exposure, avoid adding to specialty biotech until the market confirms it can support multiple expansion without fresh data catalysts; relative opportunity currently looks better in earlier-stage or faster-readthrough oncology platforms.